Paper Details

  1. Home
  2. Paper Details

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study.

Author: CatteauGrégory, DescampsDominique, DionneMarc, DobbelaereKurt, FergusonLinda M, HillemannsPeter, PetersKlaus, RamjattanBrian, RomanowskiBarbara, SchuindAnne, SchulzeKarin, SchwarzTino F

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The HPV-16/18 vaccine, administered in a 2-dose schedule, was immunogenic and well-tolerated in girls aged 9-14 years, suggesting that it may be adequate for younger females.
Paper Details　
Original Abstract of the Article :
The immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine (Cervarix®, GlaxoSmithKline Biologicals) administered according to its licensed vaccination schedule (3-dose, 3D) and formulation (20 μg of each HPV antigen; 20/20F) has previously been demonstrated. This partially-bl...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338934/

データ提供：米国国立医学図書館（NLM）

A Two-Dose Vaccine for HPV: Shorter Journey, Same Destination?

The world of [human papillomavirus (HPV)] vaccination is always evolving, searching for better ways to protect against this common virus. This research focuses on the [HPV-16/18 AS04-adjuvanted vaccine], exploring the possibility of a shorter vaccination schedule, just two doses instead of the traditional three. It's like taking a shortcut through the desert, trying to reach the same destination of immunity in a faster and more convenient way. The study found that the two-dose schedule might be just as effective as the three-dose one, especially for younger girls, offering a potentially more convenient path to protection.

A More Convenient Route to Immunity: Two-Dose HPV Vaccine Shows Promise

This research suggests that a two-dose schedule for the [HPV-16/18 AS04-adjuvanted vaccine] might be as effective as the traditional three-dose schedule, especially for girls aged 9-14. This could significantly increase vaccination rates, making it easier to protect more people from this common and potentially harmful virus. It's like finding a well-paved road through the desert, making the journey to protection more efficient and accessible.

The Oasis of Protection: Navigating the Desert of HPV

While this research offers a promising new path, it's essential to discuss vaccination options with healthcare professionals. The best choice will depend on individual needs and circumstances. Remember, just like the desert has its own dangers, so does the world of HPV. Staying hydrated with information, seeking guidance, and getting vaccinated can help keep you safe and healthy in this vast landscape.

Dr. Camel's Conclusion

This research sheds light on a potentially more convenient path to HPV protection, especially for younger generations. While the journey may be shortened, the destination of immunity remains the same. Remember, like the desert, the world of HPV can be vast and unpredictable. Seeking knowledge, staying informed, and taking the right steps can help navigate this landscape safely and effectively.

Date :
  1. Date Completed 2012-04-24
  2. Date Revised 2022-03-10
Further Info :

Pubmed ID

22048171

DOI: Digital Object Identifier

PMC3338934

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.